07:57:29 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-28 Årsstämma 2025
2024-10-24 Bokslutskommuniké 2024
2024-07-25 Kvartalsrapport 2024-Q3
2024-04-25 Kvartalsrapport 2024-Q2
2024-01-25 Kvartalsrapport 2024-Q1
2023-12-01 Ordinarie utdelning NXTCL 0.00 SEK
2023-11-30 Årsstämma 2024
2023-10-26 Bokslutskommuniké 2023
2023-07-27 Kvartalsrapport 2023-Q3
2023-04-27 Kvartalsrapport 2023-Q2
2023-01-26 Kvartalsrapport 2023-Q1
2022-11-25 Ordinarie utdelning NXTCL 0.00 SEK
2022-11-24 Årsstämma 2023
2022-10-27 Bokslutskommuniké 2022
2022-07-28 Kvartalsrapport 2022-Q3
2022-04-28 Kvartalsrapport 2022-Q2
2022-01-27 Kvartalsrapport 2022-Q1
2021-11-25 Ordinarie utdelning NXTCL 0.00 SEK
2021-11-24 Årsstämma 2022
2021-10-29 Bokslutskommuniké 2021
2021-07-30 Kvartalsrapport 2021-Q3
2021-04-29 Kvartalsrapport 2021-Q2
2021-01-29 Kvartalsrapport 2021-Q1
2020-11-25 Ordinarie utdelning NXTCL 0.00 SEK
2020-11-24 Årsstämma 2021
2020-10-30 Bokslutskommuniké 2020
2020-07-31 Kvartalsrapport 2020-Q3
2020-06-03 Extra Bolagsstämma 2020
2020-04-30 Kvartalsrapport 2020-Q2
2020-01-31 Kvartalsrapport 2020-Q1
2019-12-06 Ordinarie utdelning NXTCL 0.00 SEK
2019-12-05 Årsstämma 2020
2019-10-31 Bokslutskommuniké 2019
2019-07-31 Kvartalsrapport 2019-Q3
2019-04-30 Kvartalsrapport 2019-Q2
2019-01-31 Kvartalsrapport 2019-Q1
2018-12-05 Årsstämma 2018
2018-11-01 Ordinarie utdelning NXTCL 0.00 SEK
2018-10-31 Bokslutskommuniké 2017
2018-07-31 Kvartalsrapport 2017-Q3
2017-12-06 Ordinarie utdelning NXTCL 0.00 SEK
2017-12-05 Årsstämma 2017

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
NextCell Pharma innehar verksamhet inom hälsovårdssektorn. Idag sker utveckling av stamcellsprodukter som huvudsakligen används vid behandling av autoimmun diabetes och vid njurtransplantation. En stor del av arbetet består av stamcellsforskning där bolaget för närvarande utvecklar läkemedelskandidater som skall underlätta och öka acceptansen vid organtransplantation. Utöver innehar bolaget en stamcellsbank. Bolaget etablerades 2014 och har sitt huvudkontor i Huddinge.
2020-09-08 08:45:00

NextCell Pharma AB ("NextCell") today announces that the ProTrans-2 clinical trial met the primary endpoint. Patients treated with a single dose ProTrans show a statistically significant improved preservation of insulin production over 12 months, compared to patients treated with placebo (p-value < 0.05).

A total of 15 patients were included in the ProTrans-2 trial. They were randomized to receive either ProTrans (n=10), NextCell's proprietary stem cell therapy, or placebo (n=5). Treatment was blinded, ensuring that neither patients or their physicians knew whether they had received active treatment or placebo during the 12-month follow-up. After all data had been compiled and monitored by Karolinska Trial Alliance, the code was broken, and the results reviewed by Medical Statistics Unit, Karolinska Instituet.

To evaluate if ProTrans can improve beta cell function (endogenous insulin production capacity) in adult type-1 diabetes patients diagnosed within the last two years, C-peptide was measured during two hours after a Mixed Meal Tolerance Test (MMTT). The primary efficacy endpoint in ProTrans-2 was defined as delta-change of C-peptide Area Under the Curve (AUC) for MMTT, at day 372, following ProTrans/placebo infusion when compared to baseline performance prior to treatment. In other words, measuring the patient's percentage of insulin production remaining after 1 year.

C-peptide levels in placebo patients declined by -47 % (from average 48 nmol/l x 120 min, [SD=26] at baseline to 30 nmol/l x 120 min, [SD=26] at 12 months), whereas ProTrans treated patients declined with -10% (from average 96 nmol/l x 120 min, [SD=34] at baseline to 85 nmol/l x 120 min, [SD=30] at 12 months). ProTrans treated patients had a significant improvement in insulin preservation compared to placebo treated patients (p<0.05).

"Allogeneic cell therapy has again shown an effect in type-1 diabetes. This time in a randomized controlled trial", says the principal investigator Professor Per-Ola Carlsson, Uppsala University and Uppsala University Hospital.

A short presentation of the results in Swedish will be given today at 14:30 (slides in and possibility to ask questions in English). Welcome to Financial Hearings at: https://tv.streamfabriken.com/2020-09-08-press-conference or dial-in on; SE: +46856642705, UK: +443333009260, US: +18332498406.

On Thursday the 10th of September at 16:00, Professor Carlsson and the NextCell team invites you to a webcast presentation of the results and the roadmap forward for ProTrans in type-1 diabetes. The presentation is hosted by Directed Studios and can be watched at: https://youtu.be/HzV8T2kpdGI.

"Exciting results. 2 of 9 patients treated with ProTrans had increased insulin production after 1 year and in total 4 of 10 had a decrease of 5 % or less, as compared to 0 of 5 patients receiving placebo", says Mathias Svahn, CEO NextCell Pharma, AB.

Area under the curve C-peptide based on a mixed meal tolerance test (MMTT) is the gold standard measure of beta cell loss in type-1 diabetes. There were signficicant differences in endogeounus insulin production between the groups at baseline. The per protocol statistical analysis of changes in C-peptide levels were calculated in percentage. Two-sample t-test (two-tailed with equal variance) was used for p-value calculation, p=0.011. At this point, only primary endpoints have been analysed and more data will be presented when available.

A short presentation of the results in Swedish will be given today at 14:30 (slides in and possibility to ask questions in English). Welcome to Financial Hearings at: https://tv.streamfabriken.com/2020-09-08-press-conference or dial-in on; SE: +46856642705, UK: +443333009260, US: +18332498406.

On Thursday the 10th of September at 16:00, Professor Carlsson and the NextCell team invites you to a webcast presentation of the results and the roadmap forward for ProTrans in type-1 diabetes. The presentation is hosted by Direkt Studios and can be watched at: https://youtu.be/HzV8T2kpdGI.

This information is the information that NextCell Pharma AB is required to disclose under the EU Market Abuse Regulation. The information was provided by the below contact person for publication on 8[th] of September 2020.